| Prognostic Significance of Proteomics‐Discovered Circulating Inflammatory Biomarkers in Patients With Pulmonary Arterial Hypertension T Yokokawa, O Boucherat, S Martineau, SE Lemay, S Breuils‐Bonnet, ... Journal of the American Heart Association, e032888, 2024 | | 2024 |
| Seeing pulmonary hypertension through a paediatric lens: a viewpoint S Agarwal, J Fineman, DN Cornfield, CM Alvira, RT Zamanian, K Goss, ... European Respiratory Journal 63 (6), 2024 | | 2024 |
| A HIF-2α-dependent KMT2E-AS1/KMT2E axis orchestrates endothelial epigenetic and metabolic dysfunction in pulmonary hypertension SE Lemay, S Provencher, S Bonnet, F Potus, O Boucherat Annals of Translational Medicine, 2024 | | 2024 |
| Deficiency of the Deubiquitinase UCHL1 Attenuates Pulmonary Arterial Hypertension H Tang, A Gupta, SA Morrisroe, C Bao, TH Schwantes-An, G Gupta, ... Circulation, 2024 | | 2024 |
| Mendelian Randomization in Pulmonary Arterial Hypertension: Unveiling Early Insights With Promise for Future Discoveries S Provencher, BJ Arsenault, S Bonnet Journal of the American Heart Association 13 (6), e033446, 2024 | | 2024 |
| Managing Pulmonary Arterial Hypertension With Cardiopulmonary Comorbidities S Provencher, V Mai, S Bonnet Chest 165 (3), 682-691, 2024 | | 2024 |
| Single-cell and Spatial Transcriptomics Identified Fatty Acid-binding Proteins Controlling Endothelial Glycolytic and Arterial Programming in Pulmonary Hypertension B Liu, D Yi, S Li, K Ramirez, X Xia, Y Cao, H Zhao, A Tripathi, S Qiu, ... bioRxiv, 2024 | | 2024 |
| Endothelial fatty acid-binding proteins contribute to the pathogenesis of pulmonary hypertension. B Liu, D Yi, S Li, K Ramirez, X Xia, Y Cao, H Zhao, A Tripathi, S Qiu, ... Biorxiv: the Preprint Server for Biology, 2024 | | 2024 |
| Time Is Running Out in Pulmonary Arterial Hypertension: The Epigenetic Clock Is Clicking R El Kabbout, N Azhar, S Breuils-Bonnet, S Martineau, V Krishna, ... American Journal of Respiratory Cell and Molecular Biology 70 (2), 140-143, 2024 | | 2024 |
| Hypusine signaling promotes pulmonary vascular remodeling in pulmonary arterial hypertension SE Lemay, Y Grobs, C Romanet, S Martineau, M Salem, T Shimauchi, ... American Journal of Respiratory and Critical Care Medicine, 2024 | 1 | 2024 |
| RV-specific Targeting of Snai1 Rescues Pulmonary Hypertension-induced Right Ventricular Failure by Inhibiting EndMT and Fibrosis via LOXL2 Mediated Mechanism S Banerjee, VRC Onwunyi, J Hong, S Martineau, GA Fishbein, SB Bonnet, ... bioRxiv, 2024.04. 30.591766, 2024 | | 2024 |
| Exploring Integrin α5β1 as a Potential Therapeutic Target for Pulmonary Arterial Hypertension: Insights from Comprehensive Multicenter Preclinical Studies SE Lemay, MS Montesinos, Y Grobs, T Yokokawa, T Shimauchi, ... bioRxiv, 2024.05. 27.596052, 2024 | | 2024 |
| ATP Citrate Lyase Drives Vascular Remodeling Diseases Development Through Metabolic-Epigenetic Reprograming. Y Grobs, C Romanet, SE Lemay, A Bourgeois, P Voisine, C Theberge, ... bioRxiv, 2024.02. 02.578545, 2024 | | 2024 |
| Right Ventricle and Epigenetics: A Systematic Review V Toro, N Jutras-Beaudoin, O Boucherat, S Bonnet, S Provencher, ... Cells 12 (23), 2693, 2023 | 1 | 2023 |
| Defining the clinical validity of genes reported to cause pulmonary arterial hypertension CL Welch, MA Aldred, S Balachandar, D Dooijes, CA Eichstaedt, S Gräf, ... Genetics in Medicine 25 (11), 100925, 2023 | 15 | 2023 |
| Transcriptional profiling unveils molecular subgroups of adaptive and maladaptive right ventricular remodeling in pulmonary hypertension F Khassafi, P Chelladurai, C Valasarajan, SR Nayakanti, S Martineau, ... Nature cardiovascular research 2 (10), 917-936, 2023 | 8 | 2023 |
| Targeting ATP Citrate Lyase to mitigate Vascular Remodeling Pathogenesis. Y Grobs, C Romanet, A Bourgeois, SE Lemay, T Shimauchi, ... European Respiratory Journal 62 (suppl 67), 2023 | 1 | 2023 |
| Emergence of disease-specific endothelial and stromal cell populations responsible for arterial remodeling during development of pulmonary arterial hypertension ND Cober, E McCourt, RS Godoy, Y Deng, K Schlosser, A Situ, DP Cook, ... bioRxiv, 2023.09. 06.555321, 2023 | 2 | 2023 |
| The future of group 2 pulmonary hypertension: Exploring clinical trials and therapeutic targets C Awada, O Boucherat, S Provencher, S Bonnet, F Potus Vascular Pharmacology 151, 107180, 2023 | 3 | 2023 |
| Patients’ perceptions on clinical trials outcomes in pulmonary arterial hypertension therapy V Mai, C Gosselin, É Tremblay, G Rompré, AC Lajoie, J Weatherald, ... thorax 78 (7), 721-725, 2023 | 3 | 2023 |
Olivier BoucheratVerified email at criucpq.ulaval.ca
